ReviewScientifica2025
Efficacy and Safety of Oral Isotretinoin in Plane Warts: A Systematic Review on Clinical Studies.
Review in Scientifica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human papillomavirus-induced plane warts represent benign cutaneous lesions that, despite frequent spontaneous resolution, demonstrate persistence and recurrence patterns associated with considerable cosmetic and psychological morbidity. Isotretinoin has emerged as a therapeutic consideration for recalcitrant plane warts. We evaluated isotretinoin effectiveness and safety in the management of plane warts through a systematic analysis of available clinical evidence. Methods: We conducted this systematic review following Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines, with prospective registration in PROSPERO (ID: CRD420251060689). Comprehensive searches of PubMed, Scopus, and EMBASE databases were extended through November 2024. Primary efficacy outcomes focused on isotretinoin-induced changes in wart lesion characteristics. Results: Fifteen studies met the inclusion criteria, comprising six clinical trials, one cross-sectional study, six case reports, and two case series conducted across seven countries, encompassing 438 patients. Complete resolution rates demonstrated substantial variation, ranging from 38% to 87.5%. Among 10 studies documenting adverse events, cheilitis and dry skin emerged as the most common side effects. Conclusion: Oral isotretinoin shows promise for recalcitrant plane warts, but current evidence is heterogeneous and largely of moderate-to-low quality. These findings are insufficient to support routine clinical use at this time; well-designed, adequately powered randomized controlled trials with standardized dosing and outcomes are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.